Pitcairn Co. Buys 7,640 Shares of Genmab A/S (NASDAQ:GMAB)

Pitcairn Co. raised its stake in shares of Genmab A/S (NASDAQ:GMAB) by 70.1% in the fourth quarter, Holdings Channel reports. The fund owned 18,541 shares of the company’s stock after acquiring an additional 7,640 shares during the period. Pitcairn Co.’s holdings in Genmab A/S were worth $387,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares in the last quarter. Cromwell Holdings LLC raised its stake in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of Genmab A/S in the 4th quarter worth approximately $93,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GMAB. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Finally, Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $18.39 on Friday. The company has a 50 day moving average of $20.67 and a 200-day moving average of $21.61. Genmab A/S has a one year low of $18.30 and a one year high of $30.41. The stock has a market cap of $12.17 billion, a price-to-earnings ratio of 10.57, a P/E/G ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Equities research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.